How Safe Is Conversion from Tacrolimus to Its Generic Drug?—A Single Center Experience

DOI: 10.4236/ojneph.2012.24012   PDF   HTML     3,703 Downloads   6,176 Views   Citations

Abstract

Background: Generically produced cyclosporine has long been approved in the treatment of organ transplant recipients and several publications have dealt with its use. For tacrolimus, however, very few data exist for safety and efficacy after conversion to its generic in kidney transplant recipients. Methods: In this single-center observational study, 14 kidney transplant carriers were converted to generic tacrolimus as part of aftercare, and graft function, fasting tacrolimus levels and the daily tacrolimus dose was pursued for up to 95 weeks. Results: Average drug doses changed from 3.64 ± 1.88 mg/day with the original to 3.33 ± 1.72 mg/day after conversion to generic tacrolimus (p = 0.33). Tacrolimus fasting levels were 6.23 ± 1.68 ng/ml before and 5.89 ± 1.15 ng/ml after conversion (p = 0.66). Average serum creatinine values of 2.26 ± 1.08 mg/dl after conversion did not differ from previous values of 1.99 ± 0.74 mg/dl (p = 0.15). Conclusions: These data support the assumption, that it is safe to convert stable kidney transplant patients from the original galenic formulation under close scrutiny to the generically produced substance. Conversion is easy to be implemented in the routine follow-up and thus represents an option in the therapy with calcineurin inhibitors, which will contribute to cost reduction in the health system.

Share and Cite:

T. Marsen, "How Safe Is Conversion from Tacrolimus to Its Generic Drug?—A Single Center Experience," Open Journal of Nephrology, Vol. 2 No. 4, 2012, pp. 72-77. doi: 10.4236/ojneph.2012.24012.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] S. Pollard, B. Nashan, A. Johnston, P. Hoyer, P. Belitsky, P. Keown and H. Helderman, “A Pharmacokinetic and Clinical Review of the Potential Clinical Impact of Using Different Formulations of Cyclosporine A,” Clinical Therapeutics, Vol. 25, No. 6, 2003, pp. 1654-1669. doi:10.1016/S0149-2918(03)80161-3
[2] W. Carnahan and T. Y. Cooper, “Neoral to Gengraf Conversion in Renal Transplant Recipients,” Transplantation Proceedings, Vol. 35, No. 4, 2003, pp. 1308-1313. doi:10.1016/S0041-1345(03)00423-8
[3] J. S. Al Wakeel, F. A. Shaheen, M. C. Mathew, H. M. Abouzeinab, A. Al Afi, N. M. Tarif, M. S. Mousawi, T. S. Mahmoud, A. S. Alorrayad, E. A. Fagir, R. S. Dham and D. S. Shaker, “Six-month Clinical Outcome of Cyclosporine Microemulsion Formulation (Sigmasporin Microral) in Stable Renal Transplant Patients Previously Maintained on Sandimmun Neoral,” Transplantation Proceedings, Vol. 40, No. 7, 2008, pp. 2245-2251. doi:10.1016/j.transproceed.2008.06.044
[4] H. Müller, S. Solari, C. Zu?iga, C. Pedreros, J. Troncoso, C. Morente, R. Ovalle, P. Acosta, T. Chavez and E. Albornoz, “Immunosuppression with Generic Tacrolimus and Mycophenolate Mofetil in Renal Transplant Recipients: Preliminary Report in Chile,” Transplantation Proceedings, Vol. 40, No. 3, 2008, pp. 705-707. doi:10.1016/j.transproceed.2008.02.056
[5] “Public Assessment Report of the Medicines Evaluation Board in the Netherlands,” http://db.cbg-meb.n/mri/par/nih-1340-001-002-003.pdf.
[6] T. R. Türk, O. Witzke and M. Zeier, “KDIGO-Leitlinien Zur Betreuung von Nierentransplantatempf?ngern,” Nephrologe, Vol 5, No. 2, 2010, pp. 94-107. doi:10.1007/s11560-009-0369-6
[7] Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group, “KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients,” American Journal of Transplantation, Vol. 9, Suppl. 3, 2009, pp. S1-S155. doi:10.1111/j.1600-6143.2009.02834.x
[8] J. D. Momper, T. A. Ridenour, K. S. Schonder, R. Shapiro, A. Humar and R. Venkatarmanan, “The Impact of Conversion from Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients with Stable Graft Function,” American Journal of Transplantation, Vol. 11, No. 9, 2011, pp. 1861-1867. doi:10.1111/j.1600-6143.2011.03615.x
[9] G. B. Klintmalm, “Immunosuppression, Generic Drugs and the FDA,” American Journal of Transplantation, Vol. 11, No. 9, 2011, pp. 1765-1766. doi:10.1111/j.1600-6143.2011.03616.x
[10] J. H. Helderman, N. Kang, A. P. Legoretta and J. Y. Chen, “Healthcare Costs in Renal Transplant Recipients Using Branded versus Generic Cyclosporine,” Applied Health Economics and Health Policy, Vol. 8, No. 1, 2010, pp. 61-68.
[11] L. M. McDevitt-Potter, B. Sadaka, E. M. Tichy, C. C. Rogers and S. Gabardi, “A multicenter Experience with Generic Tacrolimus Conversion,” Transplantation, Vol. 92, No. 6, 2011, pp. 653-657. doi:10.1097/TP.0b013e31822a79ad
[12] E. G. Hagenmeyer, B. H?ussler, E. Hempel, G. Grannas, Z. Kaló, A. Kilburg and B. Nashan, “Resource Use and Treatment Costs after Kidney Tranplantation: Impact of Demographic Factors, Comorbidities, and Complications,” Transplantation, Vol. 77, No. 1, 2004, pp. 1545-1550.

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.